Key facts
- This page summarizes Dalia Megiddo's Form 3 filing for Nasus Pharma Ltd (NSRX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2026, 20:56.
Dalia Megiddo - 18 Mar 2026 Form 3 Insider Report for Nasus Pharma Ltd (NSRX)
- Reporting relationship
- Chief Development Officer, Director, Founder
- Issuer ticker
- NSRX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Dalia Megiddo
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Dalia Megiddo filed Form 3 for Nasus Pharma Ltd (NSRX) on 27 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001599618
Primary reporting owner
Megiddo Dalia
- Relationship
- Chief Development Officer, Director, Founder
- Address
- P.O. BOX 284, TEL-AVIV-YAFO, ISRAEL
- Signature
- /s/ Dalia Megiddo
- Signature date
- 27 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NSRX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,888,873
- Date
- 18 Mar 2026
- Ownership
- Direct
NSRX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,195
- Date
- 18 Mar 2026
- Ownership
- By Formulex Pharma Innovations Ltd.
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Formulex Pharma Innovations Ltd. ("Formulex"). Dr. Dalia Megiddo, as a beneficial owner of Formulex, may be deemed to beneficially own the Ordinary Shares owned directly by Formulex.